Rubin Eyal
SEC CIK 1721411 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| PLX | Protalix BioTherapeutics, Inc. | SVP, CFO | 660.9K | — | — | 4 | 2022-02-25 | 2024-09-23 |
Most active insiders at PLX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bashan Dror | Pres AND CEO, Dir | $101.4K | — |
| 2 | Bar-Shalev Amos | Dir | — | $314.16 |
Rubin Eyal made no open-market trades at PLX in the last 12 months.
Transactions 4
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2024-11-05 | 2024-09-23 | PLX | Protalix BioTherapeutics, Inc. | Rubin Eyal | SVP, CFO | A - Grant | — | +90.9K | 660.9K | +16% | — |
| I | 2024-09-24 | 2024-09-23 | PLX | Protalix BioTherapeutics, Inc. | Rubin Eyal | SVP, CFO | A - Grant | — | +99.0K | 669.0K | +17% | — |
| I | 2023-08-17 | 2023-08-15 | PLX | Protalix BioTherapeutics, Inc. | Rubin Eyal | SVP, CFO | A - Grant | — | +201.9K | 570.0K | +55% | — |
| I | 2022-02-28 | 2022-02-25 | PLX | Protalix BioTherapeutics, Inc. | Rubin Eyal | SVP, CFO | A - Grant | — | +122.0K | 368.1K | +50% | — |
Purchase Sale Sale after option exercise All abbreviations